Ausgabe 5/2020
Inhalt (46 Artikel)
Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines
Yuqian Liu, Ruochen Zang, Feifei Li, Chuanqin Shi, Jianchun Zhao, Lili Zhong, Xin Wang, Jinbo Yang, Wenbao Li
W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors
Dong Liang, Hong-Ying Wang, Shu Fan, Jin Wang, Ying Shen, Chen-Ying Gao, Man-Li Wu, She-Min Lu, San-Qi Zhang, Wei Han
Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma
Chengbin Zhao, Yuyuan Gao, Ruiming Guo, Hongwei Li, Bo Yang
[HuArgI (co)-PEG5000]-induced arginine deprivation leads to autophagy dependent cell death in pancreatic cancer cells
Nathalie Khalil, Ralph J. Abi-Habib
Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells
Jie Hu, Enxin Wang, Lei Liu, Qiuhe Wang, Dongdong Xia, Wei Bai, Jun Tie, Xiaomei Li, Jie Yuan, Shuya Yang, Dongbo Jiang, Jingqi Shi, Yuanjie Sun, Jing Wang, Chunmei Zhang, Jing Niu, Kai Li, Chuangye He, Wengang Guo, Yong Lv, Hui Chen, Xulong Yuan, Tianlei Yu, Zhengyu Wang, Bohan Luo, Na Han, Ying Zhu, Zhanxin Yin, Daiming Fan, Zhuoli Zhang, Kun Yang, Guohong Han
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells
Mona Oliveira, Lourenço Luis Botelho de Santana, José Claudio Serafim, Airam Oliveira Santos, Michelle Pereira Quintino, José Tiago Menezes Correia, Fabiano Damasceno, José Ricardo Sabino, Thiago Rubens Cardim Pires, Paulo Lucas Cerqueira Coelho, Giselle Pinto de Faria Lopes, Henning Ulrich, Silvia Lima Costa, Silvio Cunha
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models
Li Wang, Chen Hu, Aoli Wang, Cheng Chen, Jiaxin Wu, Zongru Jiang, Fengming Zou, Kailin Yu, Hong Wu, Juan Liu, Wenliang Wang, Zuowei Wang, Beilei Wang, Ziping Qi, Qingwang Liu, Wenchao Wang, Lili Li, Jian Ge, Jing Liu, Qingsong Liu
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth
Jungjoong Hwang, Insuk Song, Kwangho Lee, Hyoung Rae Kim, Eun-Hye Hong, Jung Soon Hwang, Sung-Hoon Ahn, Jongkook Lee
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells
Feng Qu, Yue Gu, Qizhi Wang, Mingzhe He, Fang Zhou, Jianguo Sun, Guangji Wang, Ying Peng
Combating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes
Hendawy OM, Mehrez E. El-Naggar, Mona El-Banna, Moustafa M. G. Fouda, Sarah I. Othman, Ahmed A. Allam, Osama M. Morsy
Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology
Omar Abuhussein, Jian Yang
Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity
Halil I. Ciftci, Mustafa Can, Doha E. Ellakwa, Salih C. Suner, Mohamed A. Ibrahim, Ayhan Oral, Nazim Sekeroglu, Barış Özalp, Masami Otsuka, Mikako Fujita, Mustafa Alparslan, Mohamed O. Radwan
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
Tao Li, Dong-Dong Jia, Li-Song Teng
Dezocine promotes T lymphocyte activation and inhibits tumor metastasis after surgery in a mouse model
Qiang Song, Geng Liu, Dongyi Liu, Chang Feng
Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonists
Agnieszka Łupicka-Słowik, Mateusz Psurski, Renata Grzywa, Monika Cuprych, Jarosław Ciekot, Waldemar Goldeman, Elżbieta Wojaczyńska, Jacek Wojaczyński, Józef Oleksyszyn, Marcin Sieńczyk
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
Laura Breen, Patricia B. Gaule, Alexandra Canonici, Naomi Walsh, Denis M. Collins, Mattia Cremona, Bryan T. Hennessy, Michael J. Duffy, John Crown, Norma O’ Donovan, Alex J. Eustace
Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types
Man-Fei Zhao, Gong-Da Liang, Yu-Jie Zhou, Zhi-Ping Chi, He Zhuang, Song-Ling Zhu, Yao Wang, Gui-Rong Liu, Jing-Bo Zhao, Shu-Lin Liu
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma
Ana M. Molina, Johannes C. van der Mijn, Paul Christos, John Wright, Charlene Thomas, Janice P. Dutcher, David M. Nanus, Scott T. Tagawa, Lorraine J. Gudas
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
Toshihiko Doi, Narikazu Boku, Yusuke Onozawa, Keishiro Takahashi, Osamu Kawaguchi, Atsushi Ohtsu
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer
Sagar Sardesai, Mohamed Badawi, Ewa Mrozek, Evan Morgan, Mitch Phelps, Julie Stephens, Lai Wei, Mahmoud Kassem, Yonghua Ling, Maryam Lustberg, Daniel Stover, Nicole Williams, Rachel Layman, Raquel Reinbolt, Jeffrey VanDeusen, Mathew Cherian, Michael Grever, William Carson, Bhuvaneswari Ramaswamy, Robert Wesolowski
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients
Alberto A. Gabizon, Esther Tahover, Talia Golan, Ravit Geva, Ruth Perets, Yasmine Amitay, Hilary Shmeeda, Patricia Ohana
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma
David C. Smith, Matthias Kroiss, Electron Kebebew, Mouhammed Amir Habra, Rashmi Chugh, Bryan J. Schneider, Martin Fassnacht, Pegah Jafarinasabian, M. Marian Ijzerman, Vivian H. Lin, Pharis Mohideen, Aung Naing
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
Geoffrey L. Uy, Sarit Assouline, Anne-Marie Young, Steven Blotner, Brian Higgins, Lin-Chi Chen, Karen Yee
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
J. Nehra, P. A. Bradbury, P. M. Ellis, J. Laskin, C. Kollmannsberger, D. Hao, R. A. Juergens, G. Goss, P. Wheatley-Price, S. J. Hotte, K. Gelmon, A. V. Tinker, P. Brown-Walker, I. Gauthier, D. Tu, X. Song, A. Khan, Lesley Seymour, M. Smoragiewicz
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K. Rowinsky, Agne Paner, Jesus G. Berdeja, Claudia Paba-Prada, Parameswaran Venugopal, Kimmo Porkka, Joachim Gullbo, Stig Linder, Angelica Loskog, Paul G. Richardson, Ola Landgren
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
K. Esther Broekman, Marieke A. J. Hof, Daan J. Touw, Jourik A. Gietema, Hans W. Nijman, Joop D. Lefrandt, An K. L. Reyners, Mathilde Jalving
Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients
Vissia Viglietta, Fuxin Shi, Qi-Ying Hu, Yong Ren, John Keilty, Heather Wolff, Ryan McCarthy, Jason Kropp, Pete Weber, John Soglia
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Frank Kroschinsky, Jan Moritz Middeke, Martin Janz, Georg Lenz, Mathias Witzens-Harig, Reda Bouabdallah, Paul La Rosée, Andreas Viardot, Gilles Salles, Seok Jin Kim, Tae Min Kim, Oliver Ottmann, Joerg Chromik, Anne-Marie Quinson, Ute von Wangenheim, Ute Burkard, Andreas Berk, Norbert Schmitz
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR
James M. Cleary, Emiliano Calvo, Victor Moreno, Dejan Juric, Geoffrey I. Shapiro, Carol Ann Vanderwal, Beibei Hu, Maryella Gifford, David Barch, Lisa Roberts-Rapp, Peter J. Ansell, Hao Xiong, Christopher Ocampo, Anthony W. Tolcher
First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors
Naohiro Okano, Daisuke Naruge, Kirio Kawai, Takaaki Kobayashi, Fumio Nagashima, Hitoshi Endou, Junji Furuse
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
Andreas Johne, Holger Scheible, Andreas Becker, Jan Jaap van Lier, Peter Wolna, Michael Meyring
Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors
Nataliya V. Uboha, Sam J. Lubner, Noelle K. LoConte, Daniel L. Mulkerin, Jens C. Eickhoff, Dustin A. Deming
Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir
Huixin Yu, Julie M. Janssen, Vincent A. de Weger, Bastiaan Nuijen, Rik E. Stuurman, Serena Marchetti, Jan H. M. Schellens, Jos H. Beijnen, Thomas P. C. Dorlo, Alwin D. R. Huitema
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer
Lipika Goyal, Surendra Pal Chaudhary, Eunice L. Kwak, Thomas A. Abrams, Amanda N. Carpenter, Brian M. Wolpin, Raymond C. Wadlow, Jill N. Allen, Rebecca Heist, Nadine Jackson McCleary, Jennifer A. Chan, Wolfram Goessling, Deborah Schrag, Kimmie Ng, Peter C. Enzinger, David P. Ryan, Jeffrey W. Clark
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
Kenichi Inoue, Masato Takahashi, Hirofumi Mukai, Takashi Yamanaka, Chiyomi Egawa, Yukinori Sakata, Hiroki Ikezawa, Toshiyuki Matsuoka, Junji Tsurutani
A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
Paul L. Swiecicki, Greg Durm, Emily Bellile, Apurva Bhangale, J. Chad Brenner, Francis P. Worden
Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
Zhichao Tian, Huimin Liu, Fan Zhang, Liangyu Li, Xinhui Du, Chao Li, Jinpo Yang, Jiaqiang Wang
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Antje Wick, Annick Desjardins, Cristina Suarez, Peter Forsyth, Ivelina Gueorguieva, Tiana Burkholder, Ann Louise Cleverly, Shawn T. Estrem, Shuaicheng Wang, Michael M. Lahn, Susan C. Guba, David Capper, Jordi Rodon
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial
Soledad Iseas, Enrique L. Roca, Juan M. O’Connor, Martin Eleta, Analia Sanchez-Luceros, Daniela Di Leo, Marcelo Tinelli, Maria L. Fara, Eduardo Spitzer, Ignacio A. Demarco, Giselle V. Ripoll, Marina Pifano, Juan Garona, Daniel F. Alonso
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
Nobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, Teresa Morán, Vanesa Gregorc, Jonathan Dowell, Hiroshi Sakai, Kiyotaka Yoh, Makoto Nishio, Alexis B. Cortot, Karim A. Benhadji, Nital Soni, Jinhong Huang, Lukas Makris, Susana Cedres
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia
Satoko Oka, Kazuo Ono, Masaharu Nohgawa
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis
Jean-Michel Lavoie, Teresa Mitchell, Sung-Eun Lee, Balvir Deol, Stephen K. Chia, Karen A. Gelmon, Christian K. Kollmannsberger, Anna V. Tinker, Steven J. M. Jones, Marco Marra, Janessa Laskin, Daniel J. Renouf
Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience
Anupama Suresh, Akannsha Ganju, Evan Morgan, Marilly Palettas, Julie A. Stephens, Joseph Liu, Michael Berger, Craig Vargo, Anne Noonan, Raquel Reinbolt, Mathew Cherian, Jeffrey VanDeusen, Sagar Sardesai, Robert Wesolowski, Daniel G. Stover, Maryam Lustberg, Bhuvaneswari Ramaswamy, Nicole Williams
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
Hiroto Inoue, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Kazuaki Yasui, Hirofumi Ogawa, Tsuyoshi Onoe, Masahiro Endo, Hideyuki Harada, Toshiaki Takahashi
Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood
Holly A. Maulhardt, Alyson M. Marin, Gere S. diZerega
Dasatinib-induced chylothorax: report of a case and review of the literature
Bojiang Chen, Zuohong Wu, Qin Wang, Weimin Li, Deyun Cheng